<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Global response to antimicrobial resistance |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="<br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p>" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="Global response to antimicrobial resistance |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Global response to antimicrobial resistance |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, University of Bologna" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="a-brief-history-of-antimicrobial-resistance-amr.html"/>
<link rel="next" href="what-are-the-drivers-of-antimicrobial-resistance.html"/>
<script src="assets/header-attrs-2.11/header-attrs.js"></script>
<script src="assets/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="assets/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="assets/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="assets/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome to the online course lecture notes</a></li>
<li class="chapter" data-level="" data-path="module-1-global-aspects-of-antimicrobial-resistance.html"><a href="module-1-global-aspects-of-antimicrobial-resistance.html"><i class="fa fa-check"></i>Module 1: Global Aspects of Antimicrobial Resistance</a>
<ul>
<li class="chapter" data-level="" data-path="a-brief-history-of-antimicrobial-resistance-amr.html"><a href="a-brief-history-of-antimicrobial-resistance-amr.html"><i class="fa fa-check"></i>A brief history of antimicrobial resistance (AMR)</a></li>
<li class="chapter" data-level="" data-path="global-response-to-antimicrobial-resistance.html"><a href="global-response-to-antimicrobial-resistance.html"><i class="fa fa-check"></i>Global response to antimicrobial resistance</a></li>
<li class="chapter" data-level="" data-path="what-are-the-drivers-of-antimicrobial-resistance.html"><a href="what-are-the-drivers-of-antimicrobial-resistance.html"><i class="fa fa-check"></i>What are the drivers of antimicrobial resistance?</a></li>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html"><i class="fa fa-check"></i>AMR in Low-Middle Income Countries (LMICs)</a>
<ul>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html#how-can-the-effectiveness-of-antimicrobials-be-preserved"><i class="fa fa-check"></i>How can the effectiveness of antimicrobials be preserved?</a></li>
<li class="chapter" data-level="" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html#case-study-a-successful-national-antibiotic-stewardship-program-in-a-lmic"><i class="fa fa-check"></i>Case study: A successful national antibiotic stewardship program in a LMIC</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="amr-situation-in-italy.html"><a href="amr-situation-in-italy.html"><i class="fa fa-check"></i>AMR situation in Italy</a></li>
<li class="chapter" data-level="" data-path="the-global-future-of-amr.html"><a href="the-global-future-of-amr.html"><i class="fa fa-check"></i>The global future of AMR</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html"><i class="fa fa-check"></i>One-Health Perspective of AMR</a>
<ul>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#antibiotic-use-in-animal-food-production"><i class="fa fa-check"></i>Antibiotic use in animal food production</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#the-impact-of-animal-antibiotic-use-on-human-amr"><i class="fa fa-check"></i>The impact of animal antibiotic use on human AMR</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#antimicrobial-resistance-in-animals-in-lmics"><i class="fa fa-check"></i>Antimicrobial resistance in animals in LMICs</a></li>
<li class="chapter" data-level="" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#environmental-concerns"><i class="fa fa-check"></i>Environmental concerns</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cross-border-spread-of-amr.html"><a href="cross-border-spread-of-amr.html"><i class="fa fa-check"></i>Cross-border spread of AMR</a></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="lecture-slides.html"><a href="lecture-slides.html"><i class="fa fa-check"></i>Lecture Slides</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="module-2the-public-health-crisis-of-new-antibiotic-development.html"><a href="module-2the-public-health-crisis-of-new-antibiotic-development.html"><i class="fa fa-check"></i>Module 2:The Public Health Crisis of New Antibiotic Development</a>
<ul>
<li class="chapter" data-level="" data-path="background.html"><a href="background.html"><i class="fa fa-check"></i>Background</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html"><i class="fa fa-check"></i>Why has antibiotic discovery faltered in recent years?</a>
<ul>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#scientific-challenges"><i class="fa fa-check"></i>Scientific challenges</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#antibiotic-regulatory-hurdles"><i class="fa fa-check"></i>Antibiotic regulatory hurdles</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><i class="fa fa-check"></i>What are the current strategies to incentive antibiotic development?</a>
<ul>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html#antibiotic-supply-chain-problems"><i class="fa fa-check"></i>Antibiotic supply chain problems</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><i class="fa fa-check"></i>What can be done to ensure antibiotic access in LMICs?</a>
<ul>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-1-weak-drug-discovery-difficulties-in-market-entry-and-poor-stewardship-lead-to-irrational-selection-and-use-of-antibiotics"><i class="fa fa-check"></i>Barrier 1: Weak drug discovery, difficulties in market entry, and poor stewardship lead to irrational selection and use of antibiotics</a></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-2-antibiotics-are-not-affordable-for-many-in-lmics-and-government-funding-for-health-is-low"><i class="fa fa-check"></i>Barrier 2: Antibiotics are not affordable for many in LMICs and government funding for health is low</a></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html"><a href="what-can-be-done-to-ensure-antibiotic-access-in-lmics.html#barrier-3-weak-health-systems-unreliable-supply-chains-and-poor-quality-control-fail-to-deliver-antibiotics-to-patients-in-need"><i class="fa fa-check"></i>Barrier 3: Weak health systems, unreliable supply chains and poor quality control fail to deliver antibiotics to patients in need</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary-1.html"><a href="summary-1.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="lecture-slides-1.html"><a href="lecture-slides-1.html"><i class="fa fa-check"></i>Lecture Slides</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="module-3-antibiotic-and-diagnostic-test-availability-affordibility.html"><a href="module-3-antibiotic-and-diagnostic-test-availability-affordibility.html"><i class="fa fa-check"></i>Module 3: Antibiotic and diagnostic test availability, affordibility</a>
<ul>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><i class="fa fa-check"></i>COVID-19 Vaccine Access in Low-Middle Income Countries (LMICs)</a>
<ul>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#covid-19-vaccines-global-access-covax-program"><i class="fa fa-check"></i>COVID-19 Vaccines Global Access (COVAX) Program</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#how-is-covax-working"><i class="fa fa-check"></i>How is COVAX working?</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#access-to-sars-cov-2-testing-in-lmics"><i class="fa fa-check"></i>Access to SARS-CoV-2 testing in LMICs</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#infection-control-in-lmics"><i class="fa fa-check"></i>Infection control in LMICs</a></li>
<li class="chapter" data-level="" data-path="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html"><a href="covid-19-vaccine-access-in-low-middle-income-countries-lmics.html#intensive-care-units-icus-in-lmics"><i class="fa fa-check"></i>Intensive care units (ICUs) in LMICs</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="access-to-covid-19-tools-accelerator-act.html"><a href="access-to-covid-19-tools-accelerator-act.html"><i class="fa fa-check"></i>ACCESS TO COVID-19 Tools Accelerator (ACT)</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html"><i class="fa fa-check"></i>Medicines Patent Pool</a>
<ul>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-covid-19"><i class="fa fa-check"></i>MPP and COVID-19</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-hiv"><i class="fa fa-check"></i>MPP and HIV</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#mpp-and-hepatitis-c"><i class="fa fa-check"></i>MPP and Hepatitis C</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#tuberculosis"><i class="fa fa-check"></i>Tuberculosis</a></li>
<li class="chapter" data-level="" data-path="medicines-patent-pool.html"><a href="medicines-patent-pool.html#is-the-medicines-patient-pool-working"><i class="fa fa-check"></i>Is the Medicines Patient Pool Working?</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html"><i class="fa fa-check"></i>Counterfeit Medications</a>
<ul>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html#specific-problems-with-counterfeited-antibiotics"><i class="fa fa-check"></i>Specific problems with counterfeited antibiotics</a></li>
<li class="chapter" data-level="" data-path="counterfeit-medications.html"><a href="counterfeit-medications.html#how-can-drug-counterfeiting-be-reduced"><i class="fa fa-check"></i>How can drug counterfeiting be reduced?</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="covid-19-and-lessons-for-the-amr-crises.html"><a href="covid-19-and-lessons-for-the-amr-crises.html"><i class="fa fa-check"></i>COVID-19 and lessons for the AMR crises</a></li>
<li class="chapter" data-level="" data-path="slides.html"><a href="slides.html"><i class="fa fa-check"></i>Slides</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p><img src="images/logo.png" style="width:1in" /><br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="global-response-to-antimicrobial-resistance" class="section level2 unnumbered">
<h2>Global response to antimicrobial resistance</h2>
<p>Recognizing the growing global threat of antibiotic resistance (AMR) on human health but also the economy and human development, The World Health Organization (WHO) and The Organisation for Animal Health (OIE) developed in 2001 a Global Plan for Containment of Antimicrobial Resistance that subsequently led to a <a href="https://www.who.int/publications/i/item/9789241509763">Global Action Plan for AMR</a> in 2017 and more recently a <a href="https://www.who.int/news/item/30-07-2021-call-to-action-on-antimicrobial-resistance-2021">“Call to Action on Antimicrobial Resistance”</a> in 2021. The plan outlines 21 strategies and 5 strategic objectives action plans that should be implemented in member states to address AMR. These include:</p>
<ol style="list-style-type: decimal">
<li>Improvements in the awareness and understanding of antimicrobial resistance through effective communication, education and training</li>
<li>Strengthening of knowledge and evidence base of AMR through surveillance and research</li>
<li>Reductions in the incidence of infection through effective sanitation, hygiene and infection prevention measures</li>
<li>Optimization the use of antimicrobial medicines in human and animal health</li>
<li>Development of an economic case for sustainable investment in AMR research that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions</li>
</ol>
<p>The WHO also proposed a <a href="https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf">Priority Pathogen List</a> for research and development of new antibiotics and established a global antimicrobial use and surveillance program. This list includes bacterial pathogens that are considered to be be the biggest threat to human health in addition to <em>Mycobacterium tuberculosis.</em> The WHO list breaks down pathogens into three groups:</p>
<figure>
<figcaption>
<p><strong>Table 1. WHO priority pathogens</strong></p>
</figcaption>
<table>
<colgroup>
<col width="13%" />
<col width="86%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Priority</th>
<th align="left">Pathogens included</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left"><strong>Critical</strong></td>
<td align="left"><p><em>Acinetobacter baumannii</em> (Carbapenem-resistant)</p>
<p><em>Pseudomonas aeruginosa</em> (Carbapenem-resistant)</p>
<p>Enterbacterales (3rd generation cephalosporin, carbapenem-resistant)</p></td>
</tr>
<tr class="even">
<td align="left"><strong>High</strong></td>
<td align="left"><p><em>Enterococcus faecium</em>, vancomycin-resistant</p>
<p><em>Staphylococcus aureus</em>, methicillin-resistant, vancomycin intermediate and resistant</p>
<p><em>Helicobacter pylori</em>, clarithromycin-resistant</p>
<p><em>Campylobacter</em>, fluoroquinolone-resistant</p>
<p><em>Salmonella</em> spp., fluoroquinolone-resistant</p>
<p><em>Neisseria gonorrhoeae</em>, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant</p></td>
</tr>
<tr class="odd">
<td align="left"><strong>Medium</strong></td>
<td align="left"><p><em>Streptococcus pneumoniae</em>, penicillin-non-susceptible</p>
<p><em>Haemophilus influenzae</em>, ampicillin-resistant</p>
<p><em>Shigella</em> spp., fluoroquinolone-resistant</p></td>
</tr>
</tbody>
</table>
</figure>
<p>These pathogens may exhibit multi-drug resistance (MDR), extensive drug resistance (XDR) or pan-drug resistance (PDR).<span class="citation"><sup><a href="#ref-MagiorakosEtAl2012a" role="doc-biblioref">2</a></sup></span> Difficult-to-treat resistance (DTR) is a newer definition used to define isolate resistance patterns that require the use of less-effective or more toxic “reserve” antibiotics- e.g., <em>Acinetobacter baumanii</em> susceptible only to colistin and tobramycin.<span class="citation"><sup><a href="#ref-KadriEtAl2018a" role="doc-biblioref">3</a></sup></span></p>
<style>
div.blue { background-color:#e6f0ff; border-radius: 5px; padding: 20px;}
</style>
<div class="blue">
<p>MDR- resistance to one agent in at least 3 antibiotic categories; XDR- resistant except to 2 or fewer antibiotic categories; PDR- resistant to all agents in all antibiotic categories; DTR-requires the use of less-effective or more toxic “reserve” antibiotics</p>
</div>
<p><br>Currently, both the <a href="https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf">WHO</a> and <a href="https://www.oie.int/en/what-we-do/global-initiatives/antimicrobial-resistance/#ui-id-4">OIE</a> have also developed lists of antibiotics that are considered of “critical importance” for human and animal medicine. These lists help establish priorities for antimicrobial resistance surveillance and new drug development.</p>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body">
<div id="ref-MagiorakosEtAl2012a" class="csl-entry">
<div class="csl-left-margin">2 </div><div class="csl-right-inline">Magiorakos A-P, Srinivasan A, Carey RB, <em>et al.</em> <a href="https://doi.org/10.1111/j.1469-0691.2011.03570.x">Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance</a>. <em>Clinical Microbiology and Infection</em> 2012; <strong>18</strong>: 268–81.</div>
</div>
<div id="ref-KadriEtAl2018a" class="csl-entry">
<div class="csl-left-margin">3 </div><div class="csl-right-inline">Kadri SS, Adjemian J, Lai YL, <em>et al.</em> <a href="https://doi.org/10.1093/cid/ciy378">Difficult-to-<span>Treat Resistance</span> in <span class="nocase">Gram-negative Bacteremia</span> at 173 <span>US Hospitals</span>: <span>Retrospective Cohort Analysis</span> of <span>Prevalence</span>, <span>Predictors</span>, and <span>Outcome</span> of <span>Resistance</span> to <span class="nocase">All First-line Agents</span></a>. <em>Clinical Infectious Diseases</em> 2018; <strong>67</strong>: 1803–14.</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="a-brief-history-of-antimicrobial-resistance-amr.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="what-are-the-drivers-of-antimicrobial-resistance.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="assets/gitbook-2.6.7/js/app.min.js"></script>
<script src="assets/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="assets/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
},
"toolbar": {
"position": "static"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
